Intra-Class Correlation Coefficient Ignorable Clustered Randomized Trials for Detecting Treatment Effect Heterogeneity
Abstract
Accurately estimating the intra-class correlation coefficient (ICC) is crucial for adequately powering clustered randomized trials (CRTs). Challenges arise due to limited prior data on the specific outcome within the target population, making accurate ICC estimation difficult. Furthermore, ICC can vary significantly across studies, even for the same outcome, influenced by factors like study design, participant characteristics, and the specific intervention. Power calculations are extremely sensitive to ICC assumptions. Minor variation in the assumed ICC can lead to large differences in the number of clusters needed, potentially impacting trial feasibility and cost. This paper identifies a special class of CRTs aiming to detect the treatment effect heterogeneity, wherein the ICC can be completely disregarded in calculation of power and sample size. This result offers a solution for research projects lacking preliminary estimates of the ICC or facing challenges in their estimate. Moreover, this design facilitates power improvement through increasing the cluster sizes rather than the number of clusters, making it particular advantageous in the situations where expanding the number of clusters is difficult or costly. This paper provides a rigorous theoretical foundation for this class of ICC-ignorable CRTs, including mathematical proofs and practical guidance for implementation. We also present illustrative examples to demonstrate the practical implications of this approach in…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis
- Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials
- Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
- Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta‐analysis, and network meta‐analysis of randomized trials with 94,283 participants
- Screen time increases overweight and obesity risk among adolescents: a systematic review and dose-response meta-analysis
- Exposure to WHO AWaRe antibiotics and isolation of multi-drug resistant bacteria: a systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.